Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ulinastatin serving as rescue auxiliary medicament for toxic shock caused by acute abdomen

A technology of ulinastatin and medicine, which is applied in the application field of ulinastatin as the first choice medicine, and can solve the problems of undiscovered and unseen ulinastatin and the like

Inactive Publication Date: 2012-08-08
徐宗昆 +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the relationship between ulinastatin and mesenteric clamping shock, and no entries related to ulinastatin and mesenteric clamping shock have been found through domestic and foreign patent searches

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ulinastatin serving as rescue auxiliary medicament for toxic shock caused by acute abdomen
  • Application of ulinastatin serving as rescue auxiliary medicament for toxic shock caused by acute abdomen
  • Application of ulinastatin serving as rescue auxiliary medicament for toxic shock caused by acute abdomen

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental example 1 scald shock

[0021] According to the Hechter method, immerse the mice below the axillary line in hot water at 65°C for 10 seconds, and then observe the survival rate for 4 hours. One minute before immersion in hot water, 15 minutes after immersion, and 1 hour after immersion, UTI was injected into the tail vein for 3 times; the injection volume was 10ml / kg, and the control group was injected with an equal volume of normal saline. The results are shown in the table below

[0022] Protective effect of intravenous injection of ulinastatin (UTI) on scald shock in mice (X±SD)

[0023]

[0024] The results showed that ulinastatin (UTI) had a dose-dependent protective effect on scald shock in mice (r=0.9603, P<0.01), which was similar to that of APR at the same dose.

Embodiment 2

[0025] Example 2 Endotoxin shock

[0026] Escherichia coli endotoxin physiological saline solution (LD50 measured by mouse IP is 5.0121ml / kg) with 2 times LD50 of mouse IP to observe the survival number of mice in 24 hours, 5 minutes, 3 hours and 12 hours after IP endotoxin, UTI was injected into the tail vein according to the dosage in the table below, and the results are as follows.

[0027] Protective effect of intravenous injection of ulinastatin (UTI) on endotoxin shock caused by Escherichia coli in mice

[0028]

[0029]

[0030] Compared with the control group, * P** P<0.01

[0031] The results showed that after intravenous injection of ulinastatin 40000U / kg and 80000U / kg, it could improve the survival rate of Escherichia coli endotoxin shock in mice, and showed obvious protective effect, which was related to dosage.

Embodiment 3

[0032] Embodiment 3 hemorrhagic shock

[0033] In hemorrhagic shock, left ventricular contractility decreased, left ventricular output decreased, and aortic blood flow decreased. These indicators improved after intravenous ulinastatin. Administration of ulinastatin had no effect on changes in heart rate due to blood loss. Even in hemorrhagic shock, the administration of ulinastatin can improve the decreased urine output and renal blood flow. In animals without shock, ulinastatin had little effect on the circulatory system except for a slight diuretic effect.

[0034] Therefore, ulinastatin specifically improves the circulatory disturbance caused by shock. Ulinastatin can inhibit the development of shock and play an important role in blocking the vicious circle of shock.

[0035] Rat hemorrhagic shock model was prepared in the experiment. Rats were fasted overnight, anesthetized with pentobarbital sodium 45mg / kg IP, tracheal intubation, spontaneous respiration, 0.4% heparin s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a rescue medicament in the field of medical treatment, in particular to a rescue medicament, namely ulinastatin or a urinary trypsin inhibitor (UTI) for toxic shock caused by acute abdomen (particularly mesenteric angiemphraxis and the like). The medicament is a preferred medicament for the toxic shock. In the pharmacodynamic study of the ulinastatin for resisting shock, the ulinastatin also can improve the average arterial blood pressure and the average arterial blood flow of superior mesenteric artery occlusion shock of rats, and has an extremely better effect on shock rescue.

Description

technical field [0001] The present invention is a rescue medicine in the medical field, especially the application of ulinastatin as the first-choice medicine in the rescue of toxic shock, especially those caused by mesenteric vascular obstruction. Background technique [0002] Ulinastatin (U1inastain or human urinary trypsin inhibitor, Urinary Trypsin Inhibitor UTI) is a urinary trypsin inhibitor isolated and purified from male urine. It is a glycoprotein, containing 143 amino acids, and its biological The utilization rate is 100%, and the half-life is more than 40 minutes. After administration, it accumulates rapidly in the kidney and liver, reaches the peak in 5 minutes, and distributes the highest in the seminal vesicles in 2 hours. The drug is mainly excreted through the kidney, and is excreted in urine and feces 12 hours after administration. 73% and 2.3%, respectively. During the excretion process, the original drug was mainly excreted from the urine within 30 minute...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/57A61P1/00A61P7/08
Inventor 徐宗昆张少青赵炎陈子明
Owner 徐宗昆
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com